Total Funding
49
19
Total FundingGrant raised
Growth Score 49 in past quarter
-26 pts
Heat Score 19 in past quarter
-19 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
72179
Zylö Therapeutics offers an innovative sustained-release drug-delivery system.
- Scott R. Pancoast: Founder & CEOPast Role: LPATH, CEO, Chairman & Board Member
- Michael Rabin: VP of Strategy
About the Company
Zylö Therapeutics offers an innovative sustained-release drug-delivery system that was developed by Joel Friedman MD PhD, Adam Friedman MD FAAD, and Andrew Draganski PhD. The delivery system uses patented hydrogel-derived nanoparticles, called Nanopods, to deliver—in a sustained and controlled manner—notoriously hard-to-deliver therapeutic agents
through topical administration.
The company was founded in 2017 and is based in Greenville, South Carolina.